Live Evaluations
Topical Management of Atopic Dermatitis and Psoriasis: Clinical Insights for Pediatricians and Dermatology Providers: PEDS23 Seminar-in-Depth
About
CME Seminar in Depth - May 6, 2023 10:25 AM EST
Topical Management of Atopic Dermatitis and Psoriasis: Clinical Insights for Pediatricians and Dermatology Providers
This activity is supported by educational grants from Arcuits, Dermavant, and Incyte.
Learning Objectives
At the completion of this activity, participants should be better able to:
Identify challenges associated with the use of topical corticosteroids in patients with AD and psoriasis
2Review nonsteroid topical agents for the treatment of AD and psoriasis
Discuss clinical considerations for dermatology providers and pediatricians who prescribe topical therapies to patients with AD and psoriasis
Intended Audience
Faculty
Lawrence Eichenfield, MD
Professor of Dermatology and Pediatrics
Vice-Chair, Department of Dermatology
Chief, Pediatric and Adolescent Dermatology
University of California, San Diego and Rady Children’s Hospital
San Diego, CA
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
CONFLICTS OF INTEREST/DISCLOSURES
In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer.
Disclosures are as follows:
Grant/Research Support: Abbvie, Arcutis, Castle, Dermavant, Galderma, Incyte, Pfizer, Target
Consultant: AbbVie, Almirall, Arena, Aslan, Dermavant, Eli Lilly, Forte, Galderma, Incyte,Krystal, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi Genzyme, UCB and Ortho Derm
Speakers’ Bureau or Honoraria: Leo, Incyte, Pfizer, Regeneron, Sanofi
Ownership Interest: Forte (Board of Directors-options); Verrica: Board of Directors (options)
The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.